Supriya Lifescience

Supriya Lifescience Equity Turnover

The Equity Turnover of Supriya Lifescience (SUPRIYA.NS) as of Nov 13, 2026 is 0.69. In the previous year, Equity Turnover was 0.70 — a change of -1.08% (lower).

Equity Turnover

0.69

YoY

-1.08%

Last updated:

Equity Turnover of Supriya Lifescience is 2026 0.69 . Equity Turnover of Supriya Lifescience was 2025 0.70 . It decreases by -1.08% lower compared to the previous year.

The Supriya Lifescience Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2019
2.96 INR
Jan 1, 2020
2.09 INR
Jan 1, 2021
1.43 INR
Jan 1, 2022
0.84 INR
Jan 1, 2023
0.64 INR
Jan 1, 2024
0.70 INR
Jan 1, 2025
0.70 INR
Jan 1, 2026
0.69 INR
The Supriya Lifescience Equity Turnover history
YEAREquity TurnoverYoY
0.69-1.08%
0.70-0.11%
0.70+8.48%
0.64-23.56%
0.84-41.13%
1.43-31.40%
2.09-29.49%
2.96-23.95%
3.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Supriya Lifescience Stock analysis

What does Supriya Lifescience do? Supriya Lifescience Ltd. generates revenue through the manufacturing and export of active pharmaceutical ingredients (APIs) focused on niche therapeutic segments. The company produces approximately 38 API products, including Chlorphenamine Maleate, Pheniramine Maleate, and Cetirizine DiHCL, which address antihistamine, analgesic, vitamin, anesthetics, and anti-asthma therapies. These products are exported to around 86 countries, targeting pharmaceutical manufacturers and healthcare providers seeking specialized chemical compounds for drug formulations. The firm's manufacturing facilities in Maharashtra support the production of bulk drugs and pharmaceutical chemicals, with a strong emphasis on research and development to maintain its niche market position. The company's product portfolio includes specialized compounds such as Bisoprolol Fumarate, Nicorandil, and Mecobalamin, which cater to specific medical needs in cardiovascular and neurological treatments. By concentrating on high-demand therapeutic areas like antihistamines and anti-asthma solutions, Supriya Lifescience Ltd. serves pharmaceutical companies globally that require reliable sources of API raw materials. Its export-driven model ensures steady demand from international clients across diverse healthcare markets. Supriya Lifescience Ltd. leverages its research and development capabilities to develop and refine its API offerings, ensuring compliance with global pharmaceutical standards. The firm's focus on niche products allows it to differentiate itself in a competitive market, attracting buyers who prioritize specialized chemical solutions over generic alternatives. With a manufacturing base in Maharashtra, the company efficiently scales production to meet the growing global demand for its targeted therapeutic APIs. Supriya Lifescience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Supriya Lifescience stock

Equity Turnover of Supriya Lifescience is 0.69 in 2026.

Equity Turnover of Supriya Lifescience changed from 0.70 to 0.69, representing a -1.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Supriya Lifescience since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Supriya Lifescience with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Supriya Lifescience

All Key Metrics — Supriya Lifescience